Celyad falls as it voluntarily pauses CYAD-101-002 Phase Ib trial

1 March 2022

Shares of Belgium biotech Celyad Oncology (Euronext: CYAD) closed down 13.8% at 2.46 euros yesterday, after it announced it has taken the decision to voluntarily pause the CYAD-101-002 (KEYNOTE-B79) Phase Ib trial (NCT04991948).

The CYAD-101-002 trial is part of a collaboration with MSD, the ex-North America trading name of Merck & Co (NYSE: MRK). The trial is evaluating the company’s TCR Inhibitory Molecule (TIM)-based allogeneic NKG2D CAR T cell investigational therapy CYAD-101 administered concurrently with FOLFOX chemotherapy, followed by MSD’s anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with refractory metastatic colorectal cancer.

Reports of two fatalities

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK